Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $132 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Auvelity growth remains strong and there are two more Phase 3 readouts coming in Q1 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $190 from $125 at Morgan Stanley
- Axsome Therapeutics: Strategic Advancements and Market Positioning Drive Buy Rating
- Positive Outlook for Axsome Therapeutics Driven by Symbravo’s Promising Study Results and Market Potential
- Axsome Therapeutics price target raised to $212 from $195 at Mizuho
- Buy Rating for Axsome Therapeutics Driven by Promising SYMBRAVO Phase 3 Trial Results